536 related articles for article (PubMed ID: 32568473)
1. The Association Between Phosphodiesterase-5 Inhibitors and Colorectal Cancer in a National Cohort of Patients.
Sutton SS; Magagnoli J; Cummings TH; Hardin JW
Clin Transl Gastroenterol; 2020 Jun; 11(6):e00173. PubMed ID: 32568473
[TBL] [Abstract][Full Text] [Related]
2. Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction.
Buvat J; Büttner H; Hatzimouratidis K; Vendeira PA; Moncada I; Boehmer M; Henneges C; Boess FG
J Sex Med; 2013 Jun; 10(6):1592-602. PubMed ID: 23551622
[TBL] [Abstract][Full Text] [Related]
3. Erectile Dysfunction Medication Use in Veterans Eligible for Medicare Part D.
Spencer SH; Suda KJ; Smith BM; Huo Z; Bailey L; Stroupe KT
J Manag Care Spec Pharm; 2016 Jul; 22(7):818-24. PubMed ID: 27348283
[TBL] [Abstract][Full Text] [Related]
4. Effect of phosphodiesterase type 5 inhibitors on major adverse cardiovascular events and overall mortality in a large nationwide cohort of men with erectile dysfunction and cardiovascular risk factors: A retrospective, observational study based on healthcare claims and national death index data.
Kloner RA; Stanek E; Crowe CL; Singhal M; Pepe RS; Bradsher J; Rosen RC
J Sex Med; 2023 Jan; 20(1):38-48. PubMed ID: 36897243
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase Type-5 Inhibitor Prescription Patterns in the United States Among Men With Erectile Dysfunction: An Update.
Mulhall JP; Chopra I; Patel D; Hassan TA; Tang WY
J Sex Med; 2020 May; 17(5):941-948. PubMed ID: 32144034
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy and tolerance of PDE-5 in the treatment of erectile dysfunction in schizophrenic patients: A literature review].
Bacconi L; Gressier F
Encephale; 2017 Feb; 43(1):55-61. PubMed ID: 27658991
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of erectile dysfunction by phosphodiesterase-5 inhibitors and nonarteritic anterior ischemic optic neuropathy (NOIAN)].
Calvet C; Martin K; Robert G; Moore N; Eftekhari P; Farghal H; Molimard M; Ballanger P
Prog Urol; 2007 Sep; 17(5):920-7. PubMed ID: 17969789
[TBL] [Abstract][Full Text] [Related]
8. Risk of Melanoma With Phosphodiesterase Type 5 Inhibitor Use Among Patients With Erectile Dysfunction, Pulmonary Hypertension, and Lower Urinary Tract Symptoms.
Shkolyar E; Li S; Tang J; Eisenberg ML
J Sex Med; 2018 Jul; 15(7):982-989. PubMed ID: 29884444
[TBL] [Abstract][Full Text] [Related]
9. Useful Implications of Low-dose Long-term Use of PDE-5 Inhibitors.
Mostafa T
Sex Med Rev; 2016 Jul; 4(3):270-284. PubMed ID: 27871960
[TBL] [Abstract][Full Text] [Related]
10. [PDE-5 inhibitors: patients preferences].
Efremov EA; Kasatonova EV; Melnik YI; Nikushina AA
Urologiia; 2017 Jul; (3):120-126. PubMed ID: 28845950
[TBL] [Abstract][Full Text] [Related]
11. Off-Target Effect of Sildenafil on Postsurgical Erectile Dysfunction: Alternate Pathways and Localized Delivery System.
Salmasi A; Lee GT; Patel N; Goyal R; Dinizo M; Kwon YS; Modi PK; Faiena I; Kim HJ; Lee N; Hannan JL; Kohn J; Kim IY
J Sex Med; 2016 Dec; 13(12):1834-1843. PubMed ID: 27843073
[TBL] [Abstract][Full Text] [Related]
12. [Phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction: past, present and future].
Gamidov SI; Ovchinnikov RI; Popova AY; Izhbaev SK
Urologiia; 2017 Apr; (1):103-107. PubMed ID: 28394532
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus.
Vardi M; Nini A
Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD002187. PubMed ID: 17253475
[TBL] [Abstract][Full Text] [Related]
14. The association of tadalafil exposure with lower rates of major adverse cardiovascular events and mortality in a general population of men with erectile dysfunction.
Kloner RA; Stanek E; Desai K; Crowe CL; Paige Ball K; Haynes A; Rosen RC
Clin Cardiol; 2024 Feb; 47(2):e24234. PubMed ID: 38377018
[TBL] [Abstract][Full Text] [Related]
15. Sildenafil use and increased risk of incident melanoma in US men: a prospective cohort study.
Li WQ; Qureshi AA; Robinson KC; Han J
JAMA Intern Med; 2014 Jun; 174(6):964-70. PubMed ID: 24710960
[TBL] [Abstract][Full Text] [Related]
16. A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction.
Rubio-Aurioles E; Porst H; Kim ED; Montorsi F; Hackett G; Morales AM; Stuckey B; Būttner H; West TM; Huynh NN; Lenero E; Burns P; Kopernicky V
J Sex Med; 2012 May; 9(5):1418-29. PubMed ID: 22429760
[TBL] [Abstract][Full Text] [Related]
17. Ischemic optic neuropathy in male veterans prescribed phosphodiesterase-5 inhibitors.
Margo CE; French DD
Am J Ophthalmol; 2007 Mar; 143(3):538-9. PubMed ID: 17317413
[TBL] [Abstract][Full Text] [Related]
18. Use of phosphodiesterase type 5 inhibitors in assistive living and home care settings.
Iannino-Renz R; Mager D
Appl Nurs Res; 2015 Aug; 28(3):251-3. PubMed ID: 26060141
[TBL] [Abstract][Full Text] [Related]
19. A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapy.
Kim ED; Seftel AD; Goldfischer ER; Ni X; Burns PR
J Sex Med; 2014 Mar; 11(3):820-30. PubMed ID: 23841532
[TBL] [Abstract][Full Text] [Related]
20. Systematic Review of Oral Combination Therapy for Erectile Dysfunction When Phosphodiesterase Type 5 Inhibitor Monotherapy Fails.
Munk NE; Knudsen JS; Comerma-Steffensen S; Simonsen U
Sex Med Rev; 2019 Jul; 7(3):430-441. PubMed ID: 30711478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
